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Workshop on 'Intraperitoneal therapy-current status and potential uses'
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Held at the Metropole Hotel, Birmingham, UK.
Introduction
G. Blackledge
West Midlands Cancer Research Campaign Clinical Trials
Unit, Queen Elizabeth Hospital, Birmingham B15 2TH, UK.
Access to the peritoneum can now be reliably gained, either
by an indwelling catheter, or intermittent catheterisation.
The peritoneum is the major site of some diseases, especially
ovarian cancer, and metastatic spread from there is rare,
except in very advanced disease. This workshop was
organized to evaluate the various methods of gaining access
to the peritoneum, to discuss the pharmacokinetic advan-
tages of i.p. treatment, and to review existing therapeutic
data. Many phase II studies of i.p. therapy have been
reported, with encouraging results, in terms of response and
remission duration, and lack of systemic toxicity. In parti-
cular, responses have been seen to larger doses ofdrugs given
i.p. when the disease was resistant to conventional doses of
the same drugs.
Randomised studies are now needed to determine whether
i.p. therapy has any long term benefit over i.v. therapy.
Other treatment methods are being investigated i.p. In
particular, radioisotopes, either linked to antibodies or in
colloid form are being studied, and there may be a role for
biological response modifiers.
This workshop reported on all these approaches, in the
hope that rational multicentre trials may be run in future to
establish the role of i.p. therapy.
Abstracts of papers
Access to the peritoneal cavity
D.M. Luesley
Department ofObstetrics and Gynaecology, University of
Birmingham, UK.
Successful i.p. chemotherapy depends upon delivering
adequate concentrations of effective agents to the intra-
abdominal tumour although absorption may result in a
further effect via the vascular and lymphatic systems.
Effective access to the tumour may be achieved by the
placement of long term indwelling catheters or by repeated
short term catheterization. There are methodological
problems with both approaches.
Intra-abdominal adhesion formation may pose a major
obstacle to therapy. Adhesions form as a result of previous
surgery and as a result of the disease process. Although
adequate distribution of a 21 fluid load has been demon-
strated by radioisotope studies in post-operative ovarian
cancer patients repeat laparotomies have demonstrated
tumour sequestered by adhesions.
Other problems associated with access are maintenance of
catheter flow, infection and herniation. These problems can
be minimized by the lateral placement of catheters, extra-
peritoneal tunnelling, a large surface area of perforated
segment, pelvic anchoring with omentectomy and peri-
operative antibiotic cover. Additionally we have found slow
IP dextran infusion during the post-operative period to be
beneficial in maintaining access.
This approach requires carefully controlled assessment in
patients with small tumour burden.
The needlescope placement of intraperitoneal catheters
M.J. Hurst
Walsgrave Hospital, Coventry CV2 2DX, UK.
The correct placement of a peritoneal catheter is important
in peritoneal dialysis and intraperitoneal chemotherapy. A
new method has been developed that utilizes a 2.2mm
diameter rigid endoscope, known as a needlescope, to
visualize the peritoneum prior to catheter implantation
(Handt & Ash, Persp. Peritoneal Dialysis 2, 30, 1984).
Initial experience with this technique in the dialysis field
resulted in 20 immediately functioning catheters out of 21
attempts (95%), the failed catheterisation was due to
extensive intraperitoneal adhesions from previous surgery.
The early post-operative complications (occurring less than
30 days post-implantation) were as follows: Leakage - 4
(20%); migration from pelvis - 3 (15%); intraperitoneal
bleeding - 2 (10%); catheter exit site infection - 2 (10%);
wound infection - 0 (0%).
The overall catheter failure rate, for a study period of 85
patient months, was 20%. These catheters were all removed
for infective complications, occurring over 30 days post-
implantation.
In addition to inserting catheters, the needlescope has been
used to reposition two migrated catheters. This was achieved
using a pair of grasping forceps introduced via a second
puncture cannula, and avoided the need for catheter
replacement.
It is concluded that this method is viable for peritoneal
catheter implantation and repositioning under local
anaesthesia. The principal alternative method is a
laparotomy, with its high incidence of leakage, and
associated risks of general anaesthesia.
The treatment of intraperitoneal malignant disease with
monoclonal antibody guided 1311 radiotherapy
B. Ward1 2, Stephen Mather1 4, J. Shepherd2,
M. Crowther2, L. Hawkins4, K. Britton4, M. Granowska4
& M. Slevin3
lImperial Cancer Research Fund, London, WC2; 2Department
ofGynaecological Oncology, St. Bartholomew's Hospital;
3Department ofMedical Oncology, St Bartholomew's
Hospital; and 4Department ofNuclear Medicine, The
Homerton Hospital, London EC], UK.
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Seven patients with small volume ovarian carcinoma,
remaining after conventional therapy of surgery and a
platinium containing chemotherapy regimen, were treated
with i.p. monoclonal antibody guided radiotherapy. 100mCi
1311 conjugated to 10mg of monoclonal antibody were
injected i.p. in 200ml peritoneal dialysis fluid. Patients were
evaluated 3 months later; 3 had clinical progressive disease
while third-look laparotomy demonstrated progressive
disease in 3 of the remaining 4 patients. The seventh patient
did not have a third look laparotomy and is currently
inevaluable for response.
Five patients with recurrent malignant ascites not
controlled by diuretics or repeated paracentesis were
similarly treated with 75-170mCi 1311 conjugated to 10mg
monoclonal antibody. In 3 patients the ascites was controlled
for a mean of 4 months. One patient died too early to assess
the control of his ascites but tumour cells disappeared from
the ascitic fluid after therapy. In the patient whose ascites
was not controlled, a subpopulation of antigen-negative
tumour cells was demonstrated. This study was unable to
demonstrate a therapeutic benefit for i.p. injected mono-
clonal antibody guided radiotherapy for solid intra-
peritoneal tumour but suggests that it may be capable of
controlling the accumulation of antigen-positive malignant
ascites.
Intraperitoneal CA125 as a tumour marker - preliminary
findings
C.W.E. Redman, F.G. Lawton, P. Lewis, D.M. Luesley,
K.K. Chan & G. Blackledge
West Midlands Ovarian Cancer Group, West Midlands CRC
Clinical Trials Unit, Queen Elizabeth Hospital, Birmingham,
B15 2TH, UK.
In the management of epithelial ovarian cancer (EOC) there
is a need for an accurate and dynamic assessment of disease.
As EOC is largely confined to the peritoneal cavity,
intraperitoneal monitoring, using a peritoneal lavage
technique, may enhance this assessment. Theoretically,
intraperitoneal CA125 may be a more sensitive tumour
marker than its serum counterpart. We are evaluating
intraperitoneal CA125 as a marker of residual disease.
Eighty-seven diagnostic peritoneal lavages have been
performed in 48 EOC patients during the course of their
treatment. 1IN saline is instilled via a temporary (44 pats)
or chronic indwelling peritoneal catheter (4 pats), and a
sample removed after 5min. Technetium studies have shown
complete intra-abdominal distribution to have occurred
within this time interval. Placement of a temporary catheter
(a 5mmVenflon) was unsatisfactory in 25% of instances but
no significant morbidity was encountered. Peritoneal lavage
fluid (PLF) CA125 was assayed using a CIS ELSA CA125
TMRIA kit. The CA125 assay characteristics in PLF parallel
those in serum and have a virtually identical precision
profile.
PLF CA125 has been measured in 15 EOC patients with
palpable intra-abdominal disease and 25 control patients
undergoing laparoscopy. Thirteen cancer patients (87%) had
PLF CA125 levels greater than the mean +2s.d. of the
control population; the specificity was 96%. Using a cut-off
point of 35UP-1, corresponding serum CA125 levels had a
sensitivity of 100% and a specificity of 88%. Serial PLF
CA125 assays demonstrate a correlation with disease
response.
These preliminary studies demonstrate the clinical viability
of peritoneal lavage as a diagnostic procedure and suggest
that PLF CA125 is a potentially useful tumour marker.
Further studies are in progress evaluating the relative value
of PLF CA125 compared to serum CA125 in the monitoring
of small volume disease.
Pharmacokinetic principles of intraperitoneal chemotherapy
P.M. Wilkinson
Department ofClinical Pharmacology, Christie Hospital and
Holt Radium Institute, Manchester M20 9BX, UK.
The direct introduction of drug into the peritoneal cavity
(PC) has certain kinetic advantages over systemic
administration in the management of local malignancies,
typically ovarian cancer. Ideally the drug should be non-
irritant, diffuse slowly from the PC, achieve adequate
penetration of tumour deposits, not produce toxicity to
abdominal organs viz. liver, kidney and systemic absorption
should be such that haemopoietic depression is minimal. In
any therapeutic study it is important to determine two
parallel parameters:
(a)
and
(b)
AUC peritoneum
AUC plasma
Peak, peritoneal concentration (Cp)
Peak plasma concentration (C)
The peritoneal clearance, systemic distribution and
excretion should also be determined. Comparison with
systemic kinetic profiles can then be made and a more
objective assessment is then possible as to whether the i.p. or
systemic route is the more favourable method for the drug in
question. Of the current cytoxic drugs used i.p. only
mitozantrone conforms most to the above objectives with a
Cp/C of 620. Other drugs with activity against ovarian
cancer systemically have much lower values, e.g. cisplatinum
40, carboplatin 18. The potential for combination therapy
has not yet been realised and there may be advantages to
combining drugs with Cp/C at the extreme ends of the
spectrum.
Intraperitoneal chemotherapy experience in The Netherlands
Cancer Institute
J.G. McVie
Antoni van Leeuwenhoek Ziekenhuis, Plesmanlaan 121 1066
CX Amsterdam, The Netherlands.
In the last 3 years over 100 patients have been treated by us
in experimental protocols, testing intraperitoneal cisplatin,
carboplatin and mitoxantrone as single agents. Drugs have
been instilled in the peritoneal cavity according to a strict
protocol which has been developed to optimize the
procedure and to minimize complications. Most patients
have been treated with Tenckhoff catheter, a small cohort
received a subcutaneously implanted portacath. As pharmaco-
kinetic studies were part of our protocol, withdrawal of
fluid from the abdomen was essential; this was rarely efficient
via the portacath system. This led to a temporary halt so
that the manufacturers could be given time to develop wider
lumen systems.
Complications from the Tenckhoff catheters were
frequently observed in the beginning stages. With increasing
experience, however, the procedure has become manageable.
Severe side effects, such as bowel perforation, bacterial
peritonitis, catheter blockage due to adhesions are now seen
in less than 10% of patients.
Patients with minimal residual disease ovarian cancer who
had failed to achieve a complete remission on intravenous
cisplatin or carboplatin combination regimes have been
entered into a series of three phase I/II studies. Thirty-two
patients have been treated with cisplatin 60-90mgnm-2 and
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of the 11 have subsequently relapsed, 3 remain in
unmaintained CR after 2.5 years of follow up. Thirty-three
patients have been treated with intraperitoneal carboplatin,
dosage ranging from 200-750mgm 2, 2 patients have
achieved remissions laparotomy proven, 1 CR is laparoscopy
proven. Side effects from carboplatin are mainly
myelosuppression and the pharmacokinetic advantage
(peritoneal exposure of drug divided by plasma exposure to
drug is 6-10. The same ratio is > 1,000 for mitoxantrone) 11
patients have been treated with mitoxantrone up to a
maximal tolerated dose of 55mgm-2 i.p. The dose limiting
toxicity is abdominal pain due to chemical peritonitis. The
phase II study has been started with infusing 25-30mgm 2
i.p. because 2 complete remissions were observed out of 11
in the phase I. Remissions have also been seen in patients
with breast cancer with metastasis predominantly limited to
the peritoneal surface. Occasional patients have been treated
with cisplatin i.p. for mesothelioma and peritoneal spread of
gastric carcinoma.
Parallel studies in the rat model have been carried out to
determine the penetration of platinum compounds and
fluorescent compounds, using sophisticated techniques,
whereby drugs can be localized and measured in the tumour.
Cytotoxic levels of cisplatin have been proved to be achieved
at 2mm within a tumour nodule in this system by
application of proton induced X-ray emission and confirmed
by application of a polyclonal antibody to platin DNA
adducts. Results of carboplatin and mitoxantrone in the rat
are not yet mature enough for reporting. The intraperitoneal
system remains a good model for experimental chemo-
therapy and immunotherapy.
Intraperitoneal chemotherapy remains an experimental
technique. It should be limited to reference Centres with a
large enough infrastructure (particularly nursing care) and its
place in the treatment of peritoneal metastases requires to be
evaluated in randomized trials compared to intravenous
chemotherapy and/or radiation to the abdomen.
Intraperitoneal chemotherapy of epithelial ovarian cancer
[EOC] with mitozantrone and cisplatinum
F. Lawton, C. Redman, D. Luesley & G. Blackledge
Departments ofGynaecology and Medicine, University of
Birmingham, UK.
Patients with small volume residual EOC with disease
confined to the peritoneal cavity might be suitable
candidates to receive active chemotherapy by the i.p. route.
Cisplatinum [D] is the most active single agent but its
systemic delivery is limited to a dose of about 100mgm-2
by nephrotoxicity. Toxicity can be limited and higher doses
[200+mgm-2] given by the i.p. route.
There are pharmacokinetic advantages in giving
mitozantrone [M], active as a single agent in EOC, by the
i.p. route, since it is non-vesicant and it exhibits a steep
dose/response curve in EOC. When used in i.v. combination
[MI4mgm-2 and D100mg m-2] dose limiting marrow
suppression is seen by the 4th cycle. Five patients [pts], 2
previously untreated and 3 previously treated with 3 cycles
of IVMD, aged 53 to 71, with FIGO stage III EOC and
macroscopic intra-abdominal residual disease [3 pts<2 cm
masses, 2pts>2cm] have been treated with M20-25mgm-2
and D 120-180mg m -2. Drug administration was either by
long-term indwelling catheter or by a cannula removed after
each treatment. The drugs were delivered sequentially into
the peritoneal cavity in 2 1N saline with a dwell time of
1 h for M and 4h for D.
Systemic toxicity was minimal. Only 2 of 15 cycles
produced>WHO grade II haematological toxicity; 4pts had
grade II emesis and 2pts had grade I alopecia. 4pts had
minimal and short lived abdominal discomfort during drug
administration. This approach needs further evaluation in
EOC.
Antibody-guided radiotherapy
A.A. Epenetos
Department ofClinical Oncology, Royal Postgraduate
Medical School, London W12 OHS, UK.
Twenty four patients with persistent epithelial ovarian cancer
after chemotherapy+external beam irradiation, were treated
with intraperitoneally administered 131I iodine labelled
monoclonal antibodies HMFG1, HMFG2, AUA1, H17E2,
directed against tumour associated antigens. Acute side
effects were mild abdominal pain, pyrexia, diarrhoea and
moderate reversible pantocytopenia. One patient developed a
subphrenic abscess requiring surgical drainage. Eight patients
with large volume disease, i.e., >2cm tumour diameter did
not respond to antibody guided irradiation and died of
progressive disease within 9 months of treatment. Sixteen
patients had small volume (<2cm) disease at the time to
treatment with radiolabelled antibody. Seven patients failed
to respond and out of 9 initial responders, 4 patients remain
alive and free from disease 6 months to 3 years after
treatment. Analysis of the data on relapse indicated that
doses > 140MCi were more effective than lower doses.
We conclude that i.p. administration of 140mCi or more
of 1311 labelled tumour associated monoclonal antibodies,
represents a new and potentially effective form of therapy
for patients with small volume stage III ovarian cancer.
The potential role of biological response modifiers in
intraperitoneal therapy
P. Selby
Section ofMedicine, Institute ofCancer Research, Royal
Marsden Hospital, Sutton.
Several biological response modifiers have now been
identified and the genes for them have been cloned, meaning
that adequate supplies for therapeutic trials can be produced.
One possible compound with antitumour effects in vitro is
tumour necrosis factor (TNF). A phase I study of human
recombinant TNF has been carried out on 18 patients,
treated intravenously. The compound produced febrile
reactions at all doses although these were preventable by
steroids and indomethacin. Doses at or above 9 x I05 units
(400 igm-2) were associated with hypotension, abnormal
liver enzymes, leucopenia and mild renal impairment in a
substantial proportion of patients. TNF was cleared from the
plasma with a half life of -20min, but non-linear
pharmacokinetics were seen with decreased clearance at
higher levels. In three patients, all with lymphoma,
improvements in their tumours were recorded.
The levels achieved intravenously are somewhat lower
than those associated with regression of most murine
experimental tumours. The use of intraperitoneal
administration may mean that high concentrations of TNF
can be delivered to tumour cells on the peritoneum.
Additionally there is evidence in vitro that TNF has a
synergistic action with other biological response modifiers.
These factors suggest that this group of compounds may
have a role to play in intraperitoneal therapy.